Sarepta prelim Q4 revenue $235.5M, FY $843.3M, exceeding guidance

Sarepta Therapeutics, Inc.

2022-FY EPS reported -$8.03 revenue$933,013,000

Preliminary Q4 2022 net product revenue ~$235.5M, up 32% YoY.
Full-year 2022 net product revenue ~$843.3M, up 38% YoY, exceeding guidance of $825-840M.
Year-end cash balance ~$2.0B, down slightly from $2.1B at end of 2021.
Revenues from three RNA-based PMO therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45.
Final Q4/FY results expected in late February 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Sarepta Therapeutics, Inc. reported year ended December 31, 2022 results: revenue approximately $843.3 million.

Period: year ended December 31, 2022
Revenue: approximately $843.3 million
Result: preliminary results

Exact text from the filing

expects total net product revenue (unaudited) for the year ended December 31, 2022 to be approximately $843.3 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Sarepta Therapeutics, Inc. reported fourth quarter ended December 31, 2022 results: revenue approximately $235.5 million.

Period: fourth quarter ended December 31, 2022
Revenue: approximately $235.5 million
Result: preliminary results

Exact text from the filing

the Company expects total net product revenue (unaudited) for the fourth quarter ended December 31, 2022 to be approximately $235.5 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000495

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.